We are live on ! Find out more
VBIV

VBI Vaccines, Inc. New Common Stock (Canada)
VBIV

Delisted

VBIV was delisted on the 7th of August, 2024.

Back to rankings

126 hedge funds and large institutions have $347M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 43 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more call options, than puts

Call options by funds: $4.42M | Put options by funds: $4.18M

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less funds holding

Funds holding: 134 → 126 (-8)

10% less capital invested

Capital invested by funds: $384M → $347M (-$37.2M)

16% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 43

33% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 24

Holders
126
Holders Change
-8
Holders Change %
-5.97%
% of All Funds
2.2%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
36
Reduced
43
Closed
24
Calls
$4.42M
Puts
$4.18M
Net Calls
+$238K
Net Calls Change
+$1.34M

Top Buyers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$2.77M
2
Millennium Management
Millennium Management
New York
+$1.5M
3
UBS Group
UBS Group
Switzerland
+$1.28M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$757K
5
Group One Trading
Group One Trading
Illinois
+$603K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$5.92M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.05M
3
FWM
Frontier Wealth Management
Missouri
-$1.9M
4
Citigroup
Citigroup
New York
-$1.81M
5
State Street
State Street
Massachusetts
-$1.47M

VBIV Hedge Fund Activity: Q3 2021 in Review

126 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q3 2021, worth a combined $347M — down 9.7% from $384M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of VBIV and 16 opened new positions — a net loss of 8 holders — while 43 trimmed existing stakes and 36 added.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $2.77M. The largest seller was Citadel Advisors, cutting an estimated $5.92M.

  • 126 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q3 2021, down from 134 in Q2 2021.
  • Funds reported $347M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q3 2021, down 9.7% quarter-over-quarter.
  • 16 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q3 2021 and 24 closed out, a net change of -8 holders.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q3 2021 was Balyasny Asset Management, an estimated $2.77M added.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q3 2021 was Citadel Advisors, an estimated $5.92M sold.

Based on aggregated 13F filings for Q3 2021.